Bartter's syndrome with normal urinary excretion of prostaglandin E: therapeutic effects of propranolol, spironolactone, indomethacin and potassium chloride.
Urinary excretion of prostaglandin E (PGE) in 8 patients with Bartter's syndrome measured by the radioimmunoassay method was not augmented over the normal values. In one of them, urinary excretion of sodium, potassium, chloride and PGE, serum sodium, potassium and chloride, plasma renin activity and plasma aldosterone concentration were studied before and after the administration of propranolol, spironolactone, indomethacin and potassium chloride. Neither propranolol nor spironolactone affected any of these parameters. Indomethacin promptly reduced urinary excretion of sodium, potassium, chloride and PGE, and markedly suppressed the renin-aldosterone system. Serum potassium was elevated, but remained still in hypokalemic range. Potassium chloride was most effective in raising the serum potassium level during the first 4 weeks of administration. These results suggest that overproduction of renal PGs is not the primary cause of Bartter's syndrome, and that the renal potassium wastage is one of the etiological factors in this syndrome. It has also been suggested that hyperreninemia in this syndrome was associated in some way with renal PGs, not PGE but other series of PGs.
D000328:Adult; D001477:Bartter Syndrome / Q000188:drug therapy / Q000652:urine*; D005260:Female; D006801:Humans; D006929:Hyperaldosteronism / Q000652:urine*; D007213:Indomethacin / Q000627:therapeutic use*; D008297:Male; D011189:Potassium Chloride / Q000627:therapeutic use*; D011433:Propranolol / Q000627:therapeutic use*; D011458:Prostaglandins E / Q000652:urine*; D013148:Spironolactone / Q000627:therapeutic use*
D011458:Prostaglandins E; D013148:Spironolactone; D011189:Potassium Chloride; D011433:Propranolol; D007213:Indomethacin